First Patient Dosed in Phase I Study of SCB-313 for MPE by Clover Biopharmaceuticals

International clinical-stage biotechnology engaged in generating new and transformative biologic treatments, Clover Biopharmaceuticals publicized today how they had dosed their first patient in a Phase I trial of SCB-313 in Australia for treating cancer patients having malignant pleural effusions. SCB-313 is a fully-human TRAIL-Trimer fusion protein.

Presently, there are 5 clinical researches in China and Australia investigating SCB-....

Click here to read more

Tags : 5 clinical researches, First Patient Dosed, SCB-313, Phase I Study, MPE , Clover Biopharmaceuticals,

SHARE THIS ARTICLE

What are you searching for?

Healthcare

First Patient Dosed in Phase I Study of SCB-313 for MPE by Clover Biopharmaceuticals

Published On 26 Nov 2019 09:43 AM

Recent Posts

According to the White House, Biden was not exposed to the question regarding Israel's decision to postpone its ground invasion of Gaza.

Asia's leading graphite producer, China, will restrict exports of a crucial battery material.

Japan requests Google to reverse the names of contested islets in the East China Sea.

Israel Rectifies Greta Thunberg's Post Regarding Gaza By Stating, "Hamas Doesn't..."

"A great deal of suffering": Jews in Europe anticipate an increase in antisemitism in the wake of the Hamas attack.

Airport and Versailles evacuations are prompted by French arrests following bomb concerns.

A man who is charged with bringing firearms onto the grounds of the Wisconsin State Capitol has pleaded not guilty to the misdemeanor charge.

Jeju Shinhwa World provides customized staycations for all visitors.

The GSDF Osprey makes its maiden voyage to Okinawa.

Conflict between Israel and Hamas: India demands strict compliance with international humanitarian law

Relations between Israel and its Arab neighbors in the Middle East

Eight airports in France have received security notifications.

A prospective Biden visit to Israel is fraught with political and security obstacles.

Physicians vow to oppose the government's plan to increase medical school quotas.

The economy minister of Japan pays a visit to Yasukuni Shrine prior to the autumn festival.